Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Active, not recruiting · NCT04091750 · Registry updated 2026-03-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-03-03 | NCT04091750 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Exelixis | 77 |
| Georgetown University | 73 |
| Hackensack Meridian Health | 52 |
| MedStar Franklin Square Medical Center | 2 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | United States | 37 |
| Lombardi Comprehensive Cancer Center | Washington D.C. | United States | 5 |
| Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute | Baltimore | United States | 1 |